COMBINED THERAPY FOR HYPERTENSION AND CEREBRAL BLOOD FLOW INDICATORS

Download full text PDF
Issue: 
12
Year: 
2015

I. Zapesochnaya (1), Candidate of Medical Sciences; Professor A. Avtandilov (2), MD; A. Timofeeva (2), Candidate of Medical Sciences; M. Chubarov (2), MD 1 -Nizhnevartovsk Town Polyclinic 2 -Russian Medical Academy of Postgraduate Education, Moscow

The impact of 6-month combined antihypertensive therapy with a calcium antagonist and an angiotensin-converting enzyme inhibitor (amlodipine with ramipril) on cerebral blood flow indicators in hypertensive patients working in the Far North has been evaluated.
Keywords: 
hypertension
amlodipine
combined antihypertensive therapy
Far North
ramipril
intima-media thickness
cerebral blood flow

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Erbel R., Lehmann N., M1. öhlenkamp S. et al. Subclinical coronary atherosclerosis predicts cardiovascular risk in different stages of hypertension: result of the heinz nixdorf recall study // Hypertension. – 2012; 59 (1): 44–53.
  2. Redon J., Olsen M., Cooper R. et al. Stroke mortality trends from 1990 to 2. 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure // Eur. Heart J. – 2011; 32: 1424–31.
  3. Rothwell P., Howard S., Dolan E. et al. Prognostic significance of visit-to- visit variability, maximum systolic blood pressure, and episodic hypertension // Lancet. – 2010; 375: 895–905.
  4. Sorokin E.V., Karpov Ju.A. Kombinirovannaja antigipertenzivnaja tera pija – kljuch k povysheniju effektivnosti serdechno-sosudistoj profilakti-ki // Rus. med. zhurn. – 2012; 25: 91–100.
  5. Breekveldt-Postma N., Penning-van Beest F., Siiskonen S. et al. Effect of persistent use of antihypertensives on blood pressure goal attainment // Curr. Med. Res. Opin. – 2008; 24: 1025–31.
  6. Kettani F., Dragomir A., Cote R. et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention // Stroke. – 2009; 40: 213–20.
  7. Shal'nova S.A., Kukushkin S., Manoshkina E. i dr. Arterial'naja giper tenzija i priverzhennost' k terapii // Vrach. – 2009; 12: 39–42.
  8. Jamerson K., Weber M., Bakris G. et al. on behalf of the ACCOMPLISH investigators. Benazepril plus amlodipine or hydrochlorotiazide for hypertension in high-risk patients // N. Engl. J. Med. – 2008; 359: 2417–28.
  9. Dahlof B., Sever P., Poulter N. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomised controlled trial // Lancet. – 2005; 366: 895–906.
  10. Bertrand M., Ferrari R., Remme W. et al. On behalf of the EUROPA Investigators. Synergistic effect of perindopril and calcium channel blockers in revention of cardiac events and death in coronary artery disease patients: analysis from the EUROPA study // Am. Heart J. – 2010; 159: 795–802.
  11. Law M., Morris J., Wald N. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies // BMJ. – 2009; 338: b1665.
  12. Podzolkov V.I., Tarzimanova A.I. Novaja fiksirovannaja kombinatsija ramiprila i amlodipina v lechenii arterial'noj gipertenzii // Rats. farma-kot. v kardiol. – 2015; 11 (3): 327–32.
  13. Chazova I.E., Martynjuk T.V., Ratova L.G. V fokuse vnimanija – ingibi tory angiotenzinprevraschajuschego fermenta: ramipril pri arterial'noj gipertonii // Sistemnye gipertenzii. – 2011; 3: 5–10.
  14. Rabochaja gruppa po lecheniju arterial'noj gipertonii Evropejskogo . obschestva gipertonii (European Society of Hypertension, ESH) i Evropejskogo obschestva kardiologov (European Society of Cardiology, ESC). Rekomendatsii po lecheniju arterial'noj gipertonii // Ros. kardiol. zhurn. – 2014; 1 (105): 7–94.
  15. Nambi V., Chambless L., Folsom A. et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study // J. Am. Coll. Cardiol. – 2010; 55: 1600–7.
  16. Mallareddy M., Parikh C., Peixoto A. Effect of angiotensinconverting . enzyme inhibitors on arterial stiffness in hypertension: systematic review and meta-analysis // J. Clin. Hypertens (Greenwich). – 2006; 8 (6): 398–403.
  17. Zanchetti A., Bond M., Hennig M. et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine study on Atherosclerosis (ELsA), a randomized, double-blind, long-term trial // Circulation. – 2002; 106: 2422–7.
  18. Kukes V.G., Ostroumova O.D., Starodubtsev A.K. Antagonisty kal'tsija: sovremennye aspekty primenenija v kardiologii // Consilium Medicum. – 2006; 8 (11): 113–7.